{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68","upperLimit":"89","value":"81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 180 days after transplant and Kaplan-Meier survival analysis was used to generate the Overall Survival estimate at 180 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"PREPARATIVE REGIMEN\\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \\*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.\n\nfludarabine phosphate: 25 mg/m2 day -7 through day -3 prior to transplant\n\nmelphalan: 140 mg/m2 day -2 prior to transplant\n\nallogeneic hematopoietic stem cell transplantation: Cells infused on Day 0 of transplant regimen\n\nintensity-modulated radiation therapy: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant","id":"OG000","title":"Treatment (Enzyme Inhibitor, Radiation Therapy, Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 180 days post-transplant","title":"Overall Survival on Day 180 Days Post-transplant","type":"SECONDARY","unitOfMeasure":"Percent Probability"}